Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

522.83
-9.7000-1.82%
Post-market: 510.00-12.8300-2.45%18:33 EDT
Volume:338.24K
Turnover:178.08M
Market Cap:22.91B
PE:18.77
High:535.33
Open:534.11
Low:520.97
Close:532.53
52wk High:549.50
52wk Low:266.98
Shares:43.83M
Float Shares:41.99M
Volume Ratio:0.54
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.86
EPS(LYR):27.86
ROE:19.71%
ROA:12.42%
PB:3.23
PE(LYR):18.77

Loading ...

Wells Fargo Reaffirms Their Hold Rating on United Therapeutics (UTHR)

TIPRANKS
·
Mar 05

United Therapeutics Director Jan Malcolm Disposes of Common Shares

Reuters
·
Mar 04

United Therapeutics Chairperson and CEO Martine A Rothblatt Disposes of Common Shares

Reuters
·
Mar 04

United Therapeutics CEO Martine Rothblatt to Present Company Overview at Leerink Global Healthcare Conference

Reuters
·
Mar 03

United Therapeutics Director Judy D. Olian Disposes of Common Shares

Reuters
·
Mar 03

United Therapeutics price target raised to $615 from $600 at Leerink

TIPRANKS
·
Mar 03

United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening

Benzinga_recent_news
·
Mar 02

United Therapeutics Shares Rise 1.3% After Co's Lung Disease Drug Succeeds Late-Stage Study

THOMSON REUTERS
·
Mar 02

United Therapeutics’ Ralinepag Trial Success Boosts PAH Outlook

TIPRANKS
·
Mar 02

United Therapeutics Corp : Leerink Partners Raises Target Price to $600 From $570

THOMSON REUTERS
·
Mar 02

United Therapeutics' drug slows progression of rare lung condition in late-stage study

Reuters
·
Mar 02

United Therapeutics Says Ralinepag Cuts PAH Clinical Worsening Risk 55% in Phase 3 ADVANCE OUTCOMES Trial

Reuters
·
Mar 02

United Therapeutics Corp - Ralinepag Treatment Well-Tolerated With Consistent Safety Profile

THOMSON REUTERS
·
Mar 02

United Therapeutics Corp - Nda for Ralinepag to Be Submitted to FDA by H2 2026

THOMSON REUTERS
·
Mar 02

United Therapeutics Corp - Phase 3 Study of Ralinepag Meets Primary Endpoint, 47% Clinical Improvement

THOMSON REUTERS
·
Mar 02

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy

THOMSON REUTERS
·
Mar 02

United Therapeutics Earnings Call Signals Growth Ahead

TIPRANKS
·
Mar 01

These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings

Benzinga
·
Feb 27

Stock Track | United Therapeutics Plummets 7.19% Intraday on Tyvaso Revenue Miss

Stock Track
·
Feb 27

United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says

MT Newswires Live
·
Feb 27